AltStreet
SEC filing record
Primary Source · SEC.gov

OrbiMed Royalty & Credit Opportunities Access Fund IV LP

Fund Vehicle2025 vintage506(b), 3(c)
Latest signalFirst saleForm D/A · 2025-03-199 events: 2 first sale, 2 sold increased, 2 investors increasedLast filing 2025-03-19

Raised

$49M

Investors

93

Min Invest

$100,000

Is this your company or fund? Claim this page free.

Claim free

AltStreet Analysis

·

Generated from EDGAR primary sources

OrbiMed Royalty & Credit Opportunities Access Fund IV LP is a Delaware limited partnership filing under Rule 506(b) and Section 3(c), managed by PPB OrbiMed Royalty Fund IV Mgt LLC and PPB Advisors LLC. This amended filing reports $48.6M raised from 93 investors with a $100K minimum investment. The fund operates in the digital IP royalties category.

This offering represents a relatively accessible entry point ($100K minimum) within the digital IP royalties space, which typically attracts accredited investors through 506(b) private placements. The 93-investor count suggests a retail-oriented or semi-institutional distribution model, moderately sized relative to the $48.6M raised to date.

Data Flags

total_amount_soldAmendment filed with significant capital ($48.6M) but entity CIK created in 2023 suggests ongoing rolling close or platform access structure
related_personsTwo separate executive officer entities listed (PPB OrbiMed Royalty Fund IV Mgt LLC and PPB Advisors LLC) indicating potential dual-manager or advisor arrangement
industry_groupIndustry group not specified on Form D despite operating in specialized digital IP royalties sector

Critical Disclosures

What the filings and the regulators have said about this entity that a reader should know first. Each line links to its source. The history, the same event across other issuers, and alerts are in the terminal.

Reporting lapsed · Form D · last filing March 19, 2025

Offering declared to continue beyond a year; annual amendment 13+ months overdue An issuer that stops filing is the case the going-concern flag cannot catch: the report that would have carried it was never filed.

Timeline
Each line is a fact as filed. The history behind it, the same event across other issuers, and an alert on the next one:Open in the terminal Watch this issuer

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001920989
Entity NameOrbiMed Royalty & Credit Opportunities Access Fund IV LP
ExemptionRule 506(b), Section 3(c), Section 3(c)(7)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising. Section 3(c) of the Investment Company Act of 1940: the issuer is a pooled investment vehicle relying on an exclusion from registration as an investment company. Section 3(c)(7) of the Investment Company Act: the fund is excluded from investment-company registration because every investor is a qualified purchaser, generally an individual with at least $5 million in investments or an institution with at least $25 million.
Entity TypeLimited Partnership
Jurisdiction of OrganizationDelaware
Issuer AddressC/O Ppb Orbimed Royalty Fund Iv Mgt LLC, 300 Barr Harbor Drive, Suite 260, West Conshohocken, PA 19428
Phone(484) 278-4017
Industry / Fund TypePooled Investment Fund · Other Investment Fund
Investment Company ActExcluded under Section 3(c)(7) (qualified purchasers only)
Securities TypePooled Investment Fund, Other
First Sale Date—
Filing DateMarch 19, 2025
Accession Number0002018824-25-000002
Total Offering AmountIndefinite
Total Amount Sold$48,625,000
Total Investors93
Non-Accredited InvestorsNone
Minimum Investment$100,000
Offering DurationIntended to last more than one year
Sales Commissions$0
Finders' Fees$0
Net Asset Value RangeDecline to Disclose
State (Issuer Address)PA
Amendment Count3 amendments filed

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

D/AMarch 19, 2025D/AMarch 19, 2025D/AMarch 20, 2024D/AApril 18, 2023DApril 4, 2022

Capital Raise Timeline

4 Form D filings from Apr 4, 2022 to Mar 19, 2025, the latest a D/A.

Checking access…

In the Terminal

Filing events

9

latest Mar 19, 2025

Critical / warning

0 / 0

7 watch · 2 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

1

dark

Latest event First sale · Mar 19, 2025

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Fund family Part of the OrbiMed Royalty & Credit Opportunities Access Fund family: 2 vehicles across 2 generations · full family and the filing behind each link in the terminal

Investor

  • The full fund family and any related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
  • 9 filing events with values and deltas, latest 2025-03-19, and alerts on the next one
  • 1 offering timeline: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Brendan Lake

Executive Officer · Conshohocken, PA

N/A PPB OrbiMed Royalty Fund IV Mgt LLC

Executive Officer · Conshohocken, PA

N/A PPB Advisors LLC

Executive Officer · Conshohocken, PA

Questions About OrbiMed Royalty & Credit Opportunities Access Fund IV LP

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is OrbiMed Royalty & Credit Opportunities Access Fund IV LP?

OrbiMed Royalty & Credit Opportunities Access Fund IV LP is a Delaware limited partnership that filed a Form D with the SEC on March 19, 2025 as a other investment fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(7) for an offering of pooled investment fund interests. AltStreet links the issuer to OrbiMed Royalty & Credit Opportunities Access Fund IV LP.

Is OrbiMed Royalty & Credit Opportunities Access Fund IV LP legit?

AltStreet does not rate legitimacy; it reports the public record. OrbiMed Royalty & Credit Opportunities Access Fund IV LP filed a Form D with the SEC on March 19, 2025 claiming Rule 506(b), Section 3(c), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $48,625,000 sold to 93 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. The issuer is linked to OrbiMed Royalty & Credit Opportunities Access Fund IV LP, which AltStreet has reviewed. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is OrbiMed Royalty & Credit Opportunities Access Fund IV LP registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that OrbiMed Royalty & Credit Opportunities Access Fund IV LP claimed Rule 506(b), Section 3(c), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has OrbiMed Royalty & Credit Opportunities Access Fund IV LP raised?

OrbiMed Royalty & Credit Opportunities Access Fund IV LP reported $48,625,000 sold from 93 investors in an offering of indefinite size as of the Form D filed March 19, 2025.

Who can invest in OrbiMed Royalty & Credit Opportunities Access Fund IV LP?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $100,000.

What is the minimum investment in OrbiMed Royalty & Credit Opportunities Access Fund IV LP?

The Form D lists $100,000 as the minimum investment accepted from any outside investor as of March 19, 2025. Issuers can waive their own minimums, and the figure does not include fees.

Who is selling OrbiMed Royalty & Credit Opportunities Access Fund IV LP and how are they paid?

The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.

Who is behind OrbiMed Royalty & Credit Opportunities Access Fund IV LP?

The Form D lists 3 related persons: Brendan Lake, executive officer (Related person is managing member of the general partner of issuer); PPB OrbiMed Royalty Fund IV Mgt LLC, executive officer (Related person is general partner of issuer); PPB Advisors LLC, executive officer (Related person is investment manager of issuer). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is OrbiMed Royalty & Credit Opportunities Access Fund IV LP located?

The issuer's address on its SEC filings is C/O Ppb Orbimed Royalty Fund Iv Mgt LLC, 300 Barr Harbor Drive, Suite 260, West Conshohocken, PA 19428. Its phone number of record is 484-278-4017. It is organized under the laws of Delaware.

How long is the OrbiMed Royalty & Credit Opportunities Access Fund IV LP offering open?

The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 3 amendments are on record for this CIK.

How large is OrbiMed Royalty & Credit Opportunities Access Fund IV LP?

The issuer declined to disclose its net asset value range on the Form D, which the form permits.

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Platform verification: the separate analyst-reviewed program for platforms, with right of reply and a document library.

Claim this profile, freeVerify this entity, $480/yrPlatform verification, from $2,400/yr

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.